SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ImmunityBio converts from Immunomedics
An SI Board Since February 2023
Posts SubjectMarks Bans Symbol
1503 51 0 IBRX
Emcee:  TinfoilHat Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
885It's not yet money in the door and what the PR did for me was highlight the waitwatchwander-2/20/2025
884Market seems unimpressed…at least initially. Perhaps there is an expectation ofjargonweary12/20/2025
883Would love to know the difference between rBCG and regular BCG when used with AnRedman1234-2/20/2025
882BCG by itself is not a big revenue driver, but the new better recombinant combinRedman1234-2/20/2025
881The 2 BLA’s will make SP explode, and their closer then they appear in the mirroRedman1234-2/19/2025
880Recombinant BCG and UK approvals way ahead of schedule. PSS is playing chess notRedman1234-2/19/2025
879This BCG news is a big deal! Academic centers don't have issues getting BCG,TinfoilHat42/19/2025
878Now let's get Anktiva approved in Europe, and then a [global?] licensing deaFitzhughlaw52/19/2025
877manipulation is frustrating ..hope shorts get caught one day...PS thank you IMMUurslor22/19/2025
876Next-generation recombinant Bacillus Calmette-Gurin has undergone Phase 2 cliniczagnut132/19/2025
875Troculeucel (SNK01) and M-ceNK are both types of activated autologous NK cells. Huggenberg32/18/2025
874On the scientific front, a micro-cap NK player just got Fast Track Designation fTinfoilHat52/17/2025
873CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2025-- ImmunityBio, Inc. ( NASDAQzagnut122/14/2025
872For sure next week.TripleE3-2/14/2025
871He certainly keeps trying .......... From this morning: D. Boral Capital Maintluckydog8812/14/2025
870sec.govmannamal-2/13/2025
869PSS seems convinced he understands Anktiva's MOA. I like this ending: "End2War22/10/2025
868Investing.com SAN DIEGO, CA – Immunity Bio, Inc., a biotechnology firm specialibgscolt42/8/2025
867urologytimes.com Anktiva as a lymphocyte rescue molecule: Unlocking the power ofCCS64862/6/2025
866PSS is also the reason the company has Anktiva. One always has to weigh the goowaitwatchwander21/31/2025
865I saw that news today. I really don’t know how you separate PSS from IBRX stock?Stanley Lake 92-1/31/2025
864I am cautiously hopeful that the revenue numbers, which I don’t think we will knjargonweary31/31/2025
863Bobbseytwins - thank you for the honest and thoughtful response - it is apprecialuckydog8821/31/2025
862You fellows obviously do care to discuss politics here despite the disclaimers, bobbseytwins200171/31/2025
861Continuing what you pointed out, this certainly is not a good look today. yahooluckydog8811/31/2025
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News